Omnicare Inc

Omnicare — Q2 2014 Earnings Presentation

16 slides from Omnicare's earnings presentation, Jul 23, 2014

  1. Slide 1: Omnicare

    Omnicare

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Certain of mace lovey it i the following re fe ‘d-lookir i i vate ities Litigation Reform Act of 1995. These forward-| Hooking statements include, but are not tte to, all statements ir ue intent, belief or Current regarding Such and involve k and orleaan risks, uncertainti

  3. Slide 3: Table of Contents

    _ Gross Profit & Adjusted Operating Income. _ Appendix. Table of Contents second:-Quarter 2014 HIGhIQHts \cusssasswenimaseesarnminaemra amiss 4 Operating Metrics — Script Data Adjusted Net Income & Cash EPS....... Adjusted Operating Income by Segment Cash Flows — Cash Deploymernt....... 2014 Guidanc

  4. Slide 4: Second-Quarter 2014 Highlights

    Second-Quarter 2014 Highlights) ¢ Revenue of $1,611M; 7.2% year-over-year increase * Adjusted EBITDA of $176.2M; 4.4% year-over-year increase Adjusted operating income of $149.1M; 5.4% year-over-year increase Adjusted cash earnings per diluted share of $0.91; 7.1% higher than 2Q13 cash earnings of $

  5. Slide 5: Operating Metrics - Script Data

    Operating Metrics Script Data") Sequential Prior Year Increase / (In thousands, except %s) 202014 12014 (Decrease) _2Q2013 (Decrease) Long-Term Care Group Scripts: Generic scripts dispensed 20,671 20,853 (0.9%) 20,558 0.5% Branded scripts dispensed 3,956 4,107 (3.7%) 4,236 (6.6%) Over-the-counter sc

  6. Slide 6: Gross Profit & Adjusted Operating Income

    | Gross Profit & Adjusted Operating Income) Sequential Prior Year Increase / Increase / In millions, except per share data and %s 22014 12014 (Decrease) _2Q2013_ (Decrease) Net sales $1,610.6 $1,571.0 2.5% — $ 1,503.1 7.2% Cost of sales 1,256.4 1,212.6 3.6% 1,143.6 9.9% Gross profit $ 354.2 $ 358.5

  7. Slide 7: Adjusted Net Income & Cash EPS

    Adjusted Net Income & Cash EPS) Sequential Prior Year In Increase / In millions, except per share data and %s 202014 102014 (Decrease) _202013_ (Decrease) $ 149.1 $ 150.41 (0.7%) $ 141.5 5.4% (23.1) (3.3) (0.9%) (3. (1.3%) Adjusted income before income taxes 126.0 ©1268 (0.6%) 118.0 8% Income taxes

  8. Slide 8: Adjusted Operating Income by Segment

    Adjusted Operating Income by Segment (1) Sequential r increase / 202014 10.2014 Decieass) 2013 Cosas) In millions, except %s Long-Term Care Group let sales $1,190.4 $ 1,191.3 (0%) $ 1,159.2 3% Adjusted operating income”) 160. 162. (1%) 160.0 0% Rate 13.44% 18.61% “\7bps 13.80% — -86 bps In whole num

  9. Slide 9: Cash Flows

    Cash Flows “) Sequential Prior Year Increase / Increase / Jn millions, except %s. 2a 2014 102014 (Decrease) _2Q2013_ (Decrease) Net income / (Loss) 22.0 63, 52.2 (65.5%) $ (87.9%) (Income) / Loss from discontinued operations $ 39.3. $ (0.1) (39400.0%) $ (4.9) (902.0%) Adjustments to reconcile net in

  10. Slide 10: Cash Deployment

    Cash Deployment Sequential Prior Year Increase / Increase / In millions, except % 202014 1@2014 (Decrease) _2Q2013_ (Decrease) Net cash flows from o} spalatig activities of continuing operations (reported) $2186 $171.6 27.4% $ 160.7 36.0% Capital expenditures 21.9 26.2 (16.4%) 23.9 (8.4%) Acquisitio

  11. Slide 11: Full-Year 2014 Guidance

    Full-Year 2014 Guidance - Net sales $6.3B to $6.4B Adjusted cash earnings per diluted share from continuing operations® BOER OVS. Cash flow from continuing | operations“) $475M to $550M | Fs Previous Guidance | Current Guidance? $6.3B to $6.4B $3.64 to $3.72 $500M to $550M ‘Guidance provided on Ap,

  12. Slide 12: Appendix

    RNY ly, “yg; Omnicare Appendix

  13. Slide 13: Capital Structure

    Capital Structure Major Debt Maturity Schedule) (ing 's) [ @As of 99010 wAsof 6/30/14 | $1,500 $1,200 $900 $600 $300 | — $0 it ! 2010 2015 2020 2025 2030 2035 2040 2045 Continue to focus on leveraging our afta balance sheet to spread out and lower b ig costs -_ mn Omnicare 2033, 14 2035 nt

  14. Slide 14: Working Capital Management

    Working Capital Management Five Quarter Trend() 45, 70 40 65 35 60 30 55 25 50 20 45 15 “se 42.9 a7 53 40 39.2 10 35 5 30 2013 3a1s 4a13 1014 2014 o=Days of y i working capital have benefitted operating cash flows; cational payment to prime vendor expected in 3Q14 coupled with opportunistic working

  15. Slide 15: Selected Branded Drug Patent Expirations

    Selected Branded Drug Patent Expirations") Myfortio Micardis 1R Micardis HCT Epivir- HBV Tabs 2Q14- Launched Actonel (150MG) Evista 2014 Diovan IR Rapamune (1MG, 2MG) 4Q14 Actonel (35MG) Celebrex Exforge IR/HCT Intuniv Nexium (Caps) Oxycontin (Limited Launch) Renagel Renvela sD Cellcept (Sol.) Inveg

  16. Slide 16: Omnicare

    Omnicare

Omnicare — Q2 2014 Earnings Presentation on 6ix